A large number of new therapeutic agents have been studied for patients with relapsed/refractory follicular lymphoma (FL). Among new therapies, idelalisib, a novel PI3K inhibitor, shows promising results in the management of this disease
In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses ...
Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing numb...
The last two decades have witnessed striking advances in our understanding of the biological factors...
A large number of new therapeutic agents have been studied for patients with relapsed/refractory fol...
Follicular lymphoma (FL) is an indolent hematological disease, often responsive to the first line of...
Follicular lymphoma (FL) is an indolent B-cell malignancy with a variable course. Standard immuno-ch...
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medic...
Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% ...
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the p...
BACKGROUNDPhosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microen...
International audienceBased on substantial preclinical rationale, the restricted hematopoietic expre...
Abstract Follicular Lymphoma (FL) is the most common subtype of indolent B cell non-Hodgkin lymphoma...
Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmenta...
Follicular lymphoma (FL) is the second most common histotype of non-Hodgkin’s lymphoma and it is gen...
In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses ...
Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing numb...
The last two decades have witnessed striking advances in our understanding of the biological factors...
A large number of new therapeutic agents have been studied for patients with relapsed/refractory fol...
Follicular lymphoma (FL) is an indolent hematological disease, often responsive to the first line of...
Follicular lymphoma (FL) is an indolent B-cell malignancy with a variable course. Standard immuno-ch...
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medic...
Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% ...
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the p...
BACKGROUNDPhosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microen...
International audienceBased on substantial preclinical rationale, the restricted hematopoietic expre...
Abstract Follicular Lymphoma (FL) is the most common subtype of indolent B cell non-Hodgkin lymphoma...
Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmenta...
Follicular lymphoma (FL) is the second most common histotype of non-Hodgkin’s lymphoma and it is gen...
In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses ...
Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing numb...
The last two decades have witnessed striking advances in our understanding of the biological factors...
DOI
Add to ORKG